All 1 tracked stories fall under one category: medical-devices. Regentis Biomaterials Ltd is most often covered alongside GelrinC, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 3.1 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Regentis Biomaterials Ltd
All 1 tracked stories fall under one category: medical-devices. Regentis Biomaterials Ltd is most often covered alongside GelrinC, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 3.1 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 6.3. We currently track 1 Healthcare story that mention Regentis Biomaterials Ltd, all published on March 17, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 34 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Regentis Biomaterials Ltd. Shared-story counts are live from our verified record — not editorial picks.
Regentis Biomaterials has patented a breakthrough solvent-free manufacturing process for its GelrinC hydrogel, achieving a 400% increase in production yield. This advancement positions the company for large-scale commercialization while improving the environmental profile and cost-efficiency of its cartilage repair solution.